Home
Resources
Publications
The nociceptin/orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-lesioned Nonhuman Primate Model of Parkinson's Disease

The nociceptin/orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-lesioned Nonhuman Primate Model of Parkinson's Disease

Naomi P Visanji, Rob M A de Bie, Tom H Johnston, Andrew C McCreary, Jonathan M Brotchie, Susan H Fox

Mov Disord. 2008 Oct 15;23(13):1922-5.

PMID: 18759357

Abstract:

The anti-parkinsonian and levodopa-sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J-113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa-sparing potential of J-113397 in MPTP-lesioned marmosets. Coadministration of J-113397 (30 mg/kg) with a sub-therapeutic dose of levodopa (12.5 mg/kg) produced an anti-parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa-sparing benefits may be offset by a propensity to exacerbate dyskinesia.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP256640456	J-113397		256640-45-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: